{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T08:45:37Z","timestamp":1794645937943,"version":"4.9.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1016\/j.ygyno.2010.11.039","type":"journal-article","created":{"date-parts":[[2010,12,18]],"date-time":"2010-12-18T09:14:57Z","timestamp":1292663697000},"page":"212-217","source":"Crossref","is-referenced-by-count":65,"title":["Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin"],"prefix":"10.1016","volume":"121","author":[{"given":"Whitfield B.","family":"Growdon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Breton N.","family":"Roussel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa L.","family":"Scialabba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dora","family":"Dias-Santagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. John","family":"Iafrate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leif W.","family":"Ellisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary H.","family":"Tambouret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo R.","family":"Rueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darrell R.","family":"Borger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2010.11.039_bb0005","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1006\/gyno.2000.5956","article-title":"Chemotherapy for malignant mixed Mullerian tumors of the ovary","volume":"79","author":"Sit","year":"2000","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.11.039_bb0010","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1046\/j.1525-1438.2002.01117.x","article-title":"Analysis of clinicopathologic factors in malignant mixed Mullerian tumors of the uterine corpus","volume":"12","author":"Inthasorn","year":"2002","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2010.11.039_bb0015","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ygyno.2004.01.007","article-title":"Cisplatin as initial chemotherapy in ovarian carcinosarcomas: a Gynecologic Oncology Group study","volume":"93","author":"Thigpen","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.11.039_bb0020","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ajog.2008.04.019","article-title":"The role of radiation in improving survival for early-stage carcinosarcoma and leiomyosarcoma","volume":"199","author":"Wright","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2010.11.039_bb0025","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1200\/JCO.2006.06.4907","article-title":"Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study","volume":"25","author":"Homesley","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.11.039_bb0030","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ygyno.2009.10.053","article-title":"The impact of multi-modal therapy on survival for uterine carcinosarcomas","volume":"116","author":"Gonzalez Bosquet","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.11.039_bb0035","first-page":"5379","article-title":"Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors","volume":"57","author":"Wada","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2010.11.039_bb0040","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/(SICI)1096-9896(199712)183:4<424::AID-PATH949>3.0.CO;2-L","article-title":"Molecular genetic evidence for the conversion hypothesis of the origin of malignant mixed mullerian tumours","volume":"183","author":"Abeln","year":"1997","journal-title":"J Pathol"},{"key":"10.1016\/j.ygyno.2010.11.039_bb0045","first-page":"114","article-title":"Frequent genetic heterogeneity in the clonal evolution of gynecological carcinosarcoma and its influence on phenotypic diversity","volume":"60","author":"Fujii","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2010.11.039_bb0050","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/modpathol.3800654","article-title":"DNA mismatch repair and TP53 defects are early events in uterine carcinosarcoma tumorigenesis","volume":"19","author":"Taylor","year":"2006","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ygyno.2010.11.039_bb0055","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/01.pgp.0000092134.88121.56","article-title":"Carcinosarcomas (malignant mullerian mixed tumors) of the uterus and ovary: a genetic study with special reference to histogenesis","volume":"22","author":"Jin","year":"2003","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.ygyno.2010.11.039_bb0060","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0046-8177(98)90394-X","article-title":"Carcinosarcomas (malignant mixed mullerian tumors) of the female genital tract: comparative molecular analysis of epithelial and mesenchymal components","volume":"29","author":"Kounelis","year":"1998","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ygyno.2010.11.039_bb0065","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1046\/j.1525-1438.2002.01151.x","article-title":"Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas","volume":"12","author":"McCluggage","year":"2002","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2010.11.039_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00004347-199001000-00001","article-title":"Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases","volume":"9","author":"Silverberg","year":"1990","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.ygyno.2010.11.039_bb0075","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/jcp.55.5.321","article-title":"Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas?","volume":"55","author":"McCluggage","year":"2002","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.ygyno.2010.11.039_bb0080","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/IGC.0b013e31819a1fa5","article-title":"A clinical and biological comparison between malignant mixed mullerian tumors and grade 3 endometrioid endometrial carcinomas","volume":"19","author":"Bland","year":"2009","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2010.11.039_bb0085","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/00004347-199501000-00007","article-title":"Malignant mixed mullerian tumor versus high-grade endometrial carcinoma and aggressive variants of endometrial carcinoma: a comparative analysis of survival","volume":"14","author":"George","year":"1995","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.ygyno.2010.11.039_bb0090","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ygyno.2005.04.027","article-title":"Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer","volume":"98","author":"Amant","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.11.039_bb0095","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/IGC.0b013e3181dc8292","article-title":"Ovarian and uterine carcinosarcomas: a comparative analysis of prognostic variables and survival outcomes","volume":"20","author":"Garg","year":"2010","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2010.11.039_bb0100","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00428-007-0557-6","article-title":"Molecular genetic aberrations of ovarian and uterine carcinosarcomas\u2013a CGH and FISH study","volume":"452","author":"Schipf","year":"2008","journal-title":"Virchows Arch"},{"key":"10.1016\/j.ygyno.2010.11.039_bb0105","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ygyno.2004.07.041","article-title":"ERBB-2 gene overexpression and amplification in uterine sarcomas","volume":"95","author":"Amant","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.11.039_bb0110","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/j.1349-7006.2003.tb01389.x","article-title":"Different expression patterns of KIT, EGFR, and HER-2 (c-erbB-2) oncoproteins between epithelial and mesenchymal components in uterine carcinosarcoma","volume":"94","author":"Sawada","year":"2003","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ygyno.2010.11.039_bb0115","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ygyno.2005.07.124","article-title":"EGFR expression and HER2\/neu overexpression\/amplification in endometrial carcinosarcoma","volume":"100","author":"Livasy","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.11.039_bb0120","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.mrfmmm.2010.01.019","article-title":"Low frequency of somatic mutations in uterine sarcomas: a molecular analysis and review of the literature","volume":"686","author":"Murray","year":"2010","journal-title":"Mutat Res"},{"key":"10.1016\/j.ygyno.2010.11.039_bb0125","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1525-1438.2006.00410.x","article-title":"Expression and amplification of HER-2\/neu oncogene in uterine carcinosarcomas: a marker for potential molecularly targeted treatment?","volume":"16","author":"Raspollini","year":"2006","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2010.11.039_bb0130","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ygyno.2004.09.050","article-title":"COX-2, c-KIT and HER-2\/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies?","volume":"96","author":"Raspollini","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.11.039_bb0135","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ygyno.2006.11.001","article-title":"Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets","volume":"105","author":"Cimbaluk","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.11.039_bb0140","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/emmm.201000070","article-title":"Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine","volume":"2","author":"Dias-Santagata","year":"2010","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.ygyno.2010.11.039_bb0145","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1006\/gyno.2001.6307","article-title":"Carcinosarcoma of the uterus: immunohistochemical and genetic analysis of clonality of one case","volume":"82","author":"Watanabe","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.11.039_bb0150","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/(SICI)1097-0215(19970926)73:1<33::AID-IJC6>3.0.CO;2-2","article-title":"Amplification of the mdm-2 gene and p53 abnormalities in uterine sarcomas","volume":"73","author":"Seki","year":"1997","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ygyno.2010.11.039_bb0155","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1146\/annurev.pathol.4.110807.092246","article-title":"Ovarian cancer","volume":"4","author":"Cho","year":"2009","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.ygyno.2010.11.039_bb0160","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1146\/annurev.pathol.2.010506.091905","article-title":"Endometrial carcinoma","volume":"2","author":"Di Cristofano","year":"2007","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.ygyno.2010.11.039_bb0165","doi-asserted-by":"crossref","first-page":"10669","DOI":"10.1158\/0008-5472.CAN-05-2620","article-title":"High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma","volume":"65","author":"Oda","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2010.11.039_bb0170","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ygyno.2007.07.070","article-title":"A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus","volume":"107","author":"Wolfson","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.11.039_bb0175","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0090-8258(89)80041-1","article-title":"Management of malignant, mixed mesodermal tumors of the uterus","volume":"32","author":"Podczaski","year":"1989","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.11.039_bb0180","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/0090-8258(83)90117-8","article-title":"Adjuvant chemotherapy in early uterine sarcoma","volume":"15","author":"Hannigan","year":"1983","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.11.039_bb0185","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.ygyno.2004.11.022","article-title":"Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study","volume":"96","author":"Sutton","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.11.039_bb0190","first-page":"661","article-title":"Phase II trial of etoposide in the management of advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group Study","volume":"71","author":"Slayton","year":"1987","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.ygyno.2010.11.039_bb0195","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/1097-0142(19830815)52:4<626::AID-CNCR2820520409>3.0.CO;2-E","article-title":"A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas","volume":"52","author":"Omura","year":"1983","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2010.11.039_bb0200","first-page":"271","article-title":"Phase II trial of cisplatin in the treatment of patients with advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group Study","volume":"70","author":"Thigpen","year":"1986","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.ygyno.2010.11.039_bb0205","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0002-9378(89)90507-3","article-title":"Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study)","volume":"161","author":"Sutton","year":"1989","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2010.11.039_bb0210","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ygyno.2005.05.015","article-title":"Phase II evaluation of topotecan in carcinosarcoma of the uterus: a Gynecologic Oncology Group study","volume":"98","author":"Miller","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.11.039_bb0215","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ygyno.2010.01.013","article-title":"A phase II study of sorafenib in advanced uterine carcinoma\/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia","volume":"117","author":"Nimeiri","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.11.039_bb0220","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ygyno.2010.01.002","article-title":"Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus","volume":"117","author":"Huh","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.11.039_bb0225","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/01.pgp.0000183047.45459.36","article-title":"Immunohistochemical evaluation of KIT expression in sarcomas of the gynecologic region","volume":"25","author":"Nakayama","year":"2006","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.ygyno.2010.11.039_bb0230","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1158\/1078-0432.CCR-03-0363","article-title":"c-Kit expression in patients with uterine leiomyosarcomas: a potential alternative therapeutic treatment","volume":"10","author":"Raspollini","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2010.11.039_bb0235","doi-asserted-by":"crossref","first-page":"19936","DOI":"10.1073\/pnas.0707498104","article-title":"Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling","volume":"104","author":"McDermott","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ygyno.2010.11.039_bb0240","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1126\/science.1073096","article-title":"Cancer. Addiction to oncogenes\u2013the Achilles heal of cancer","volume":"297","author":"Weinstein","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2010.11.039_bb0245","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nature05610","article-title":"Patterns of somatic mutation in human cancer genomes","volume":"446","author":"Greenman","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2010.11.039_bb0250","doi-asserted-by":"crossref","first-page":"4392s","DOI":"10.1158\/1078-0432.CCR-06-0096","article-title":"\u201cOncogenic shock\u201d: explaining oncogene addiction through differential signal attenuation","volume":"12","author":"Sharma","year":"2006","journal-title":"Clin Cancer Res"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581000867X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581000867X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T05:57:23Z","timestamp":1544075843000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082581000867X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["S009082581000867X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2010.11.039","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]}}}